EPHA2 and small cell lung carcinoma: In SCLC, increased expression of erythropoietin-producing hepatocellular A2 (EphA2) leads to enhanced expression and activity of PRMT1, bolstering the expression of stemness-related biomarkers SOX2, thereby inducing stemness and chemoresistance in SCLC (80).